newsfilter
← Latest News
Business Wire·

Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

ZURA
  • Zura Bio Limited closed its underwritten public offering of Class A ordinary shares & pre-funded warrants on February 26, 2026.
  • The offering included 21,200,000 Class A ordinary shares priced at $6.25 per share & 1,800,000 pre-funded warrants priced at $6.249 per warrant.
  • Underwriters exercised their option to purchase an additional 3,000,000 Class A ordinary shares in full.
  • Gross proceeds from the offering totaled approximately $144 million before deducting underwriting discounts, commissions, & other expenses.
  • Leerink Partners, Piper Sandler, & Cantor served as joint bookrunning managers, while Wedbush PacGrow acted as the lead manager.
  • The offering was conducted pursuant to a shelf registration statement on Form S-3 declared effective by the SEC on September 17, 2024.
  • Zura is a clinical-stage biotechnology company developing dual-pathway antibodies for autoimmune & inflammatory diseases.
  • Lead candidate tibulizumab is currently in two Phase 2 studies for hidradenitis suppurativa & systemic sclerosis.
  • Additional candidates crebankitug & torudokimab have completed Phase 1/1b studies & are being evaluated for various autoimmune conditions.